IRVINE, Calif., Nov. 7, 2011 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the global leader in medical aesthetic products and technology featured a live demonstration of their latest technology, ePrime, on the October 27, 2011 segment of The Doctors. The audience and viewers of The Doctors witnessed first-hand the ePrime procedure and the immediate post treatment results.
(Logo: http://photos.prnewswire.com/prnh/20111107/NY99332LOGO )
ePrime stands as the only energy-based dermal remodeling device that delivers energy directly to the dermis boosting the skin’s natural production of collagen, elastin and hyaluronic acid. “ePrime is a revolutionary new technology in facial aesthetics that delivers energy directly into the skin to produce a three-dimensional improvement to the topography and volume of the skin,” said Mitch Chasin, M.D., Cosmetic Laser Specialist and Medical Director at Reflections Center for Skin and Body in Livingston and Bridgewater, New Jersey. “What sets the ePrime apart clinically from other energy-based devices is that it not only stimulates the production of new collagen, which is standard in many energy-based devices and even with popular topicals, but it has also been clinically proven to stimulate elastin and hyaluronic acid reproduction the trinity of natural youth allowing skin to not only look younger, but behave younger too.”
For the first time ePrime’s proprietary Intelligent Feedback Systems (IFS), which measures temperature in real time, allows practitioners to adjust power levels to safely and effectively meet the needs of different skin conditions and all skin types. This single treatment procedure takes less than an hour to perform under local anesthetic allowing patients to drive home safely post-treatment and return to normal activities within 24 hours.
“At Syneron we work diligently alongside our physician partners to remain at the forefront of cutting-edge applications,” said Louis P. Scafuri, Chief Executive Officer of Syneron Medical and Candela Corporation. “ePrime exemplifies our commitment to innovation as it introduces a new paradigm in controlled precision delivery of energy to a specific target which we believe will spark new and exciting advancements in the field of medical aesthetics for both face and body.”
To view The Doctor segment featuring ePrime http://www.youtube.com/watch?v=V0wYdPQ2GDc
For more information about ePrime and to locate a physician in your area, visit www.syneron.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. a company devoted to real technology, real science and real results is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company’s aspiration and commitment to innovation expands Syneron’s offering beyond medical device into the largest in-demand applications in beauty - skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing “believes,” “anticipates,” “plans,” “expects,” “may,” “will,” “would,” “intends,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
SOURCE Syneron Medical Ltd.
